NASDAQ:IMDZ Immune Design (IMDZ) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free IMDZ Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.85▼$5.8550-Day Range$5.85▼$5.8552-Week Range$1.10▼$5.85VolumeN/AAverage Volume374,216 shsMarket Capitalization$282.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immune Design alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Immune Design Stock (NASDAQ:IMDZ)Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… IMDZ Stock News HeadlinesApril 19, 2024 | msn.comStudy reveals key protein's role in balancing immune response to viral infectionsApril 8, 2024 | msn.comStudy of twins provides new insights into immune defense in the wombApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 27, 2024 | msn.com10 Immune-boosting products to add to your routineMarch 18, 2024 | msn.comMetabolic Insights into Immune Cell Activation and ResponseMarch 14, 2024 | msn.comResearchers solve mystery of how minimalist plant immune molecules become activatedMarch 8, 2024 | msn.com'Double life' of key immune protein reveals new strategies for treating cancer and autoimmune diseasesMarch 8, 2024 | msn.comImmune cells can adapt to invading pathogens, deciding whether to fight now or prepare for the next battleApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 4, 2024 | msn.comDiscovery of 'molecular machine' brings new immune therapies a step closerMarch 1, 2024 | tmcnet.comImmunis.AI Announces Publication, in The Journal of Urology, of Results from Blood-Based Immune Profiling Study for Prostate Cancer PatientsFebruary 5, 2024 | msn.com10 Best Foods to Boost Your Immune SystemJanuary 31, 2024 | msn.comWhen and how immune cells form 'memories' of pathogen encounters and respond upon reinfectionJanuary 25, 2024 | msn.comNew algorithm may greatly speed up the design of 'humanized' antibodies that workJanuary 14, 2024 | msn.comJN.1 variant's spread not due to enhanced immune escape, study suggestsJanuary 11, 2024 | msn.comSmall changes in specific immune cell populations linked to autoimmune disordersJanuary 11, 2024 | msn.comNew immune system-targeting compound shows early promise in treating lupusDecember 25, 2023 | nytimes.comWhy the World Needs Its Own Immune SystemDecember 20, 2023 | msn.comImmune system plays crucial step in creating blood stem cellsDecember 18, 2023 | msn.comResearchers develop innovative and flexible method to study immune cell capabilitiesNovember 13, 2023 | markets.businessinsider.comPromising Outlook for AC Immune SA: Buy Rating Based on Potential Alzheimer Trials Success and Encouraging ABATE Study ProgressNovember 1, 2023 | msn.comSignificance of multivitamins in supporting immune healthOctober 2, 2023 | msn.comHow to keep your immune system strong this winter – according to expertsJuly 5, 2023 | msn.comTips for building your immune system naturallyJune 23, 2023 | msn.comImmune systems can be weakened by space travel - what causes such an immune deificit? - studyMay 31, 2023 | health.usnews.comHow Aging Affects Your Immune SystemMay 16, 2023 | forbes.comDigital Immune Systems: Assurance In The Midst Of VolatilitySee More Headlines Receive IMDZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Design and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2018Today4/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:IMDZ CUSIPN/A CIK1437786 Webwww.immunedesign.com Phone206-682-0645FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,760,000.00 Net Margins-2,483.00% Pretax MarginN/A Return on Equity-49.56% Return on Assets-46.21% Debt Debt-to-Equity RatioN/A Current Ratio11.33 Quick Ratio11.32 Sales & Book Value Annual Sales$2.20 million Price / Sales128.62 Cash FlowN/A Price / Cash FlowN/A Book Value$1.91 per share Price / Book3.06Miscellaneous Outstanding Shares48,370,000Free FloatN/AMarket Cap$282.96 million OptionableOptionable Beta3.48 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Carlos V. Paya (Age 60)CEO, Pres & Director Mr. Stephen R. Brady (Age 49)Exec. VP of Strategy & Fin. Dr. Jan Henrik Ter Meulen (Age 56)Chief Scientific Officer Sylvia WheelerInvestor Relations OfficerDr. Wayne R. Gombotz (Age 60)Chief Devel. Officer Key CompetitorsRAPT TherapeuticsNASDAQ:RAPTAquestive TherapeuticsNASDAQ:AQSTXOMANASDAQ:XOMAContineum TherapeuticsNASDAQ:CTNMKamadaNASDAQ:KMDAView All Competitors IMDZ Stock Analysis - Frequently Asked Questions How were Immune Design's earnings last quarter? Immune Design Corp. (NASDAQ:IMDZ) issued its earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.01. The biotechnology company earned $0.76 million during the quarter, compared to analysts' expectations of $0.64 million. Immune Design had a negative net margin of 2,483.00% and a negative trailing twelve-month return on equity of 49.56%. What other stocks do shareholders of Immune Design own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Design investors own include Omeros (OMER), Progenics Pharmaceuticals (PGNX), Geron (GERN), Melinta Therapeutics (MLNT), Rigel Pharmaceuticals (RIGL), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Trevena (TRVN), TherapeuticsMD (TXMD) and Achaogen (AKAO). This page (NASDAQ:IMDZ) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Design Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
